Pfizer Limited announced the unaudited financial results for the quarter and nine months ended December 31, 2025, following the Board Meeting on February 9, 2026. Total Income for the quarter reached ₹683.24 crore, resulting in a Net Profit of ₹141.84 crore. The company also detailed exceptional items impacting the profit figures for the period.
Pfizer Q3 FY2026 Financial Highlights
Pfizer Limited formally announced the approval of its Unaudited Financial Results for the third quarter and the nine months ended December 31, 2025. The results were approved by the Board of Directors during a meeting held on February 9, 2026.
Quarterly Performance (3 Months Ended 31/12/2025)
Key figures for the quarter ended December 31, 2025, compared to the preceding quarter (30/09/2025) and the corresponding quarter last year (31/12/2024), are summarized below:
- Total Income: ₹683.24 crore (up from ₹684.19 crore in the preceding quarter and up from ₹580.75 crore in the corresponding quarter last year).
- Profit Before Tax and Exceptional Items: ₹250.15 crore.
- Net Profit for the Quarter: ₹141.84 crore (compared to ₹189.02 crore in the preceding quarter).
- Earnings Per Share (Basic and Diluted, before Exceptional Items): ₹40.42.
Year-to-Date Performance (Nine Months Ended 31/12/2025)
For the cumulative nine months ended December 31, 2025, the company reported:
- Total Income: ₹2,037.65 crore (compared to ₹1,817.11 crore for the same period last year).
- Net Profit for the Period: ₹522.61 crore (compared to ₹436.66 crore in the prior year period).
- Earnings Per Share (Basic and Diluted, before Exceptional Items): ₹123.65 (compared to ₹95.44 previously).
Significant Exceptional Items Noted
The results include Exceptional Items of ₹58.20 crore for the current quarter and nine months. These items primarily relate to two main events:
First, the company recorded a charge of ₹39.58 crore associated with entering an exclusive Supply and Marketing Agreement with Cipla Limited for four brands. This charge covers personnel separation costs for field force, marketing teams, and support functions.
Second, an incremental impact of ₹18.62 crore was booked due to an increase in the provision for employee benefits following the consolidation of labour laws into the ‘New Labour Codes’ effective November 21, 2025, primarily driven by a change in wage definition.
Note that exceptional items for the Year ended March 31, 2025, included a Net gain of ₹172.81 crore from the assignment of a lease and the sale of a building.
Business Structure and Audit Status
The company continues to operate solely within one segment, which is ‘Pharmaceuticals’. The financial results have been subject to a limited review by the statutory auditors, B S R & Co. LLP, and the review report confirmed that no material modifications were necessary.
Source: BSE
